Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Comparison of the Efficacy and Safety of EFGR Tyrosine Kinase Inhibitor Monotherapy with Standard Second-line Chemotherapy in Previously Treated Advanced Non-small-cell Lung Cancer: a Systematic Review and Meta-analysis

  • Qi, Wei-Xiang (Department of Oncology, the Sixth People's Hospital, Shanghai Jiao Tong University) ;
  • Shen, Zan (Department of Oncology, the Sixth People's Hospital, Shanghai Jiao Tong University) ;
  • Lin, Feng (Department of Oncology, the Sixth People's Hospital, Shanghai Jiao Tong University) ;
  • Sun, Yuan-Jue (Department of Oncology, the Sixth People's Hospital, Shanghai Jiao Tong University) ;
  • Min, Da-Liu (Department of Oncology, the Sixth People's Hospital, Shanghai Jiao Tong University) ;
  • Tang, Li-Na (Department of Oncology, the Sixth People's Hospital, Shanghai Jiao Tong University) ;
  • He, Ai-Na (Department of Oncology, the Sixth People's Hospital, Shanghai Jiao Tong University) ;
  • Yao, Yang (Department of Oncology, the Sixth People's Hospital, Shanghai Jiao Tong University)
  • Published : 2012.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To compare the efficacy and safety of epidermal growth factor receptor tyrosine kinase inhibitormonotherapy (EFGR-TKIs: gefitinib or erlotinib) with standard second-line chemotherapy (single agent docetaxel or pemetrexed) in previously treated advanced non-small-cell lung cancer (NSCLC). Methods: We systematically searched for randomized clinical trials that compared EGFR-TKI monotherapy with standard second-line chemotherapy in previously treated advanced NSCLC. The end points were overall survival (OS), progression-free survival (PFS), overall response rate (ORR), 1-year survival rate (1-year SR) and grade 3 or 4 toxicities. The pooled hazard ratio (HR) or risk ratio (RR), with their corresponding 95% confidence intervals (CI) were calculated employing fixed- or random-effects models depending on the heterogeneity of the included trials. Results: Eight randomized controlled trials (totally 3218 patients) were eligible. Our meta-analysis results showed that EGFR-TKIs were comparable to standard second-line chemotherapy for advanced NSCLC in terms of overall survival (HR 1.00, 95%CI 0.92-1.10; p=0.943), progression-free survival (HR 0.90, 95%CI 0.75-1.08, P=0.258) and 1-year-survival rate (RR 0.97, 95%CI 0.87-1.08, P=0.619), and the overall response rate was higher in patients who receiving EGFR-TKIs(RR 1.50, 95%CI 1.22-1.83, P=0.000). Sub-group analysis demonstrated that EGFR-TKI monotherapy significantly improved PFS (HR 0.73, 95%CI: 0.55-0.97, p=0.03) and ORR (RR 1.96, 95%CI: 1.46-2.63, p=0.000) in East Asian patients, but it did not translate into increase in OS and 1-year SR. Furthermore, there were fewer incidences of grade 3 or 4 neutropenia, febrile neutropenia and neutrotoxicity in EGFR-TKI monotherapy group, excluding grade 3 or 4 rash. Conclusion: Both interventions had comparable efficacy as second-line treatments for patients with advanced NSCLC, and EGFR-TKI monotherapy was associated with less toxicity and better tolerability. Moreover, our data also demonstrated that EGFR-TKImonotherapy tended to be more effective in East Asian patients in terms of PFS and ORR compared with standard second-line chemotherapy. These results should help inform decisions about patient management and design of future trials.

Keywords

References

  1. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101. https://doi.org/10.2307/2533446
  2. Cufer T, Vrdoljak E, Gaafar R, et al (2006). Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs, 17, 401-9. https://doi.org/10.1097/01.cad.0000203381.99490.ab
  3. Ciuleanu T, Stelmakh L, Cicenas S, et al (2012). Efficacy and safety of erlotinib versus chemotherapy in secondline treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol, 13, 300-8. https://doi.org/10.1016/S1470-2045(11)70385-0
  4. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  5. Fossella FV, DeVore R, Kerr RN, et al (2000). Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol, 18, 2354-62.
  6. Garassino MC, Martelli O, Bettini A, et al (2012). TAILOR:A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR. J Clin Oncol, 30, abstr LBA7501.
  7. Jiang H (2009). Overview of gefitinib in non-small cell lung cancer: an Asian perspective. Jpn J Clin Oncol, 39, 137-50.
  8. Jiang J, Huang L, Liang X, et al (2011). Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Acta Oncol, 50, 582-8. https://doi.org/10.3109/0284186X.2010.546368
  9. Kim ES, Hirsh V, Mok T, et al (2008). Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet, 372, 1809-18. https://doi.org/10.1016/S0140-6736(08)61758-4
  10. Kim ST, Uhm JE, Lee J, et al(2012). Randomized phase II study of gefitinib versus erlotinib in patients with advanced nonsmall cell lung cancer who failed previous chemotherapy. Lung Cancer, 75, 82-8. https://doi.org/10.1016/j.lungcan.2011.05.022
  11. Lee DH, Park K, Kim JH, et al (2010). Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res, 16, 1307-14. https://doi.org/10.1158/1078-0432.CCR-09-1903
  12. Li H, Zhuang Y, Xiu Y, et al (2010). Second-line treatment with gefitinib or docetaxel for advanced non-small cell lung cancer. Chin J Clin Oncol, 37, 16-8 (article in chinese).
  13. Maruyama R, Nishiwaki Y, Tamura T et al (2008). Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol, 26, 4244-52. https://doi.org/10.1200/JCO.2007.15.0185
  14. Moher D, Pham B, Jones A, et al (1998). Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet, 352, 609-13. https://doi.org/10.1016/S0140-6736(98)01085-X
  15. Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
  16. Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34. https://doi.org/10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
  17. Passaro A, Cortesi E, de Marinis F (2011). Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors? Expert Rev Anticancer Ther, 11, 1587-97. https://doi.org/10.1586/era.11.120
  18. Qi WX, Shen Z, Yao Y (2012). Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol, 69, 99-106. https://doi.org/10.1007/s00280-011-1678-9
  19. Qi WX, Tang LN, He AN, et al (2012). Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol, 138, 745-51. https://doi.org/10.1007/s00432-012-1155-9
  20. Rossi A, Ricciardi S, Maione P, et al (2009). Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer, 66, 141-9. https://doi.org/10.1016/j.lungcan.2009.06.006
  21. Schiller JH, Harrington D, Belani CP, et al (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8. https://doi.org/10.1056/NEJMoa011954
  22. Shepherd FA, Dancey J, Ramlau R, et al (2000). Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 18, 2095-103.
  23. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al (2005). Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 353, 123-32. https://doi.org/10.1056/NEJMoa050753
  24. Stinchcombe TE, Socinski MA (2009). Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy. J Thorac Oncol, 4, 243-50. https://doi.org/10.1097/JTO.0b013e31819516a6
  25. Sun JM, Lee KH, Kim SW, et al (2012). Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinumbased chemotherapy (KCSG-LU08-01): An open-label, phase 3 trial. Cancer 2012.
  26. Thatcher N, Chang A, Parikh P, et al(2005). Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 366, 1527-37. https://doi.org/10.1016/S0140-6736(05)67625-8
  27. Uhm JE, Park BB, Ahn MJ, et al (2009). Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group. J Thorac Oncol, 4, 1136-43. https://doi.org/10.1097/JTO.0b013e3181b270a7
  28. Vamvakas L, Agelaki S, Kentepozidis NK, et al (2010). Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial. J Clin Oncol, 28, abstr 7519.
  29. Vandenbroucke JP (1998). Bias in meta-analysis detected by a simple, graphical test. Experts' views are still needed. BMJ, 316, 469-70. https://doi.org/10.1136/bmj.316.7129.469
  30. Yang CH (2008). EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future. Lung Cancer, 60, S23-30.
  31. Zintzaras E, Ioannidis JP (2005). Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol, 28, 123-37. https://doi.org/10.1002/gepi.20048

Cited by

  1. Relationship between Epidermal Growth Factor Receptor Gene Mutations and Clinicopathological Features in Patients with Non-Small Cell Lung Cancer in Western Turkey vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3705
  2. Treatment of stage IIIb/IV non-small cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatment vol.30, pp.2, 2013, https://doi.org/10.1007/s12032-013-0550-7
  3. Pharmacotherapy targeting the EGFR oncogene in NSCLC vol.15, pp.16, 2014, https://doi.org/10.1517/14656566.2014.957179
  4. Efficacy of First-line Chemotherapy Affects the Second-Line Setting Response in Patients with Advanced Non-Small Cell Lung Cancer vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6799
  5. Therapeutic Effects and Adverse Drug Reactions are Affected by Icotinib Exposure and CYP2C19 and EGFR Genotypes in Chinese Non-Small Cell Lung Cancer Patients vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7195
  6. Icotinib: activity and clinical application in Chinese patients with lung cancer vol.15, pp.5, 2014, https://doi.org/10.1517/14656566.2014.890183
  7. Effectiveness and Safety of Pemetrexed Versus Docetaxel as a Treatment for Advanced Non-small Cell Lung Cancer: a Systematic Review and Meta-analysis vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3419
  8. Protein kinase inhibitors to treat non-small-cell lung cancer vol.15, pp.9, 2014, https://doi.org/10.1517/14656566.2014.909412
  9. The Efficacy and Safety of EGFR Inhibitor Monotherapy in Non-Small Cell Lung Cancer: A Systematic Review vol.16, pp.6, 2014, https://doi.org/10.1007/s11912-014-0390-4
  10. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials vol.19, pp.2, 2014, https://doi.org/10.1007/s10147-013-0561-6
  11. Second-Line Therapy in Non–Small-Cell Lung Cancer: The DELTA Between Different Genotypes Widens vol.32, pp.18, 2014, https://doi.org/10.1200/JCO.2013.54.4270
  12. Meta-Analysis of EGFR Tyrosine Kinase Inhibitors Compared with Chemotherapy as Second-Line Treatment in Pretreated Advanced Non-Small Cell Lung Cancer vol.9, pp.7, 2014, https://doi.org/10.1371/journal.pone.0102777
  13. Chemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis vol.10, pp.7, 2015, https://doi.org/10.1371/journal.pone.0131278
  14. Synthesis, Characterization and in vitro Anti-Tumoral Evaluation of Erlotinib-PCEC Nanoparticles vol.15, pp.23, 2014, https://doi.org/10.7314/APJCP.2014.15.23.10281
  15. KRAS Mutation as a Biomarker for Survival in Patients with Non-Small Cell Lung Cancer, A Meta-Analysis of 12 Randomized Trials vol.16, pp.10, 2015, https://doi.org/10.7314/APJCP.2015.16.10.4439
  16. Predictive and Prognostic Biomarkers for Patients Treated with Anti-EGFR Agents in Lung Cancer: A Systemic Review and Meta-Analysis vol.16, pp.11, 2015, https://doi.org/10.7314/APJCP.2015.16.11.4759
  17. Wasted research when systematic reviews fail to provide a complete and up-to-date evidence synthesis: the example of lung cancer vol.14, pp.1, 2016, https://doi.org/10.1186/s12916-016-0555-0
  18. DACH1 inhibits the proliferation and invasion of lung adenocarcinoma through the downregulation of peroxiredoxin 3 vol.37, pp.7, 2016, https://doi.org/10.1007/s13277-016-4811-x
  19. The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer vol.5, pp.1, 2016, https://doi.org/10.1186/s40064-016-2873-2
  20. EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients vol.95, pp.50, 2016, https://doi.org/10.1097/MD.0000000000005601
  21. Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters vol.17, pp.4, 2017, https://doi.org/10.1038/tpj.2016.31
  22. mutation-positive non-small-cell lung cancer treated in the EURTAC trial vol.11, pp.3, 2015, https://doi.org/10.2217/fon.14.269